Tofacitinib in patients with refractory Takayasu's arteritis.
作者信息
Li Jing, Li Mengtao, Tian Xinping, Zeng Xiaofeng
机构信息
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Diseases (NCRC-DID), Beijing, China.
出版信息
Rheumatology (Oxford). 2020 Nov 1;59(11):e95-e98. doi: 10.1093/rheumatology/keaa281.
Abstract
摘要
相似文献
1
Tofacitinib in patients with refractory Takayasu's arteritis.托法替布用于难治性大动脉炎患者。
Rheumatology (Oxford). 2020 Nov 1;59(11):e95-e98. doi: 10.1093/rheumatology/keaa281.
2
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases.托法替布治疗难治性大动脉炎：2例病例描述
Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):234-235. Epub 2020 Jan 9.
3
Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.托法替布成功缓解一名合并溃疡性结肠炎的难治性大动脉炎患者的病情。
Ann Rheum Dis. 2020 Aug;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606. Epub 2020 Mar 25.
4
Extended-release tofacitinib improves refractory Takayasu's arteritis.缓释托法替布可改善难治性大动脉炎。
Scand J Rheumatol. 2022 Jan;51(1):72-75. doi: 10.1080/03009742.2021.1911054. Epub 2021 Jun 9.
5
A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.一例大动脉炎合并难治性溃疡性结肠炎患者经托法替布治疗成功
Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.
6
Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara .对桑原发表的《托法替布成功治疗一名合并溃疡性结肠炎的难治性大动脉炎患者实现缓解》的评论
Ann Rheum Dis. 2022 Jun;81(6):e93. doi: 10.1136/annrheumdis-2020-217894. Epub 2020 Jun 24.
7
Improvements in PET/CT results and serum cytokine profile of HLA-B52-positive patients with Takayasu's arteritis and ulcerative colitis post-tofacitinib.托法替布治疗后，HLA - B52阳性的大动脉炎和溃疡性结肠炎患者PET/CT结果及血清细胞因子谱的改善情况。
Clin Exp Rheumatol. 2022 May;40(4):849-850. doi: 10.55563/clinexprheumatol/i9chku. Epub 2021 Jun 22.
8
Response to: 'Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara ' by Rios Rodriguez .对里奥斯·罗德里格斯所著《对桑原“关于托法替布成功治疗一名难治性大动脉炎合并溃疡性结肠炎患者的评论”的评论》的回应
Ann Rheum Dis. 2022 Jun;81(6):e94. doi: 10.1136/annrheumdis-2020-218055. Epub 2020 Jun 24.
9
Two cases of Takayasu's arteritis occurring under anti-TNF therapy.两例发生在抗 TNF 治疗中的 Takayasu 动脉炎。
Joint Bone Spine. 2013 Mar;80(2):211-3. doi: 10.1016/j.jbspin.2012.07.015. Epub 2012 Sep 19.
10
Takayasu's arteritis presenting as fever of unknown origin: report of two cases and literature review.以不明原因发热为表现的高安动脉炎：两例报告及文献复习
Semin Arthritis Rheum. 1999 Feb;28(4):280-5. doi: 10.1016/s0049-0172(99)80023-7.
引用本文的文献
1
A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.浅析大动脉炎的体液免疫反应及相关治疗方法。
Int J Mol Sci. 2024 Jun 13;25(12):6528. doi: 10.3390/ijms25126528.
2
Novel and potential future therapeutic options in systemic autoimmune diseases.系统性自身免疫性疾病的新型和潜在未来治疗选择。
Front Immunol. 2024 Mar 15;15:1249500. doi: 10.3389/fimmu.2024.1249500. eCollection 2024.
3
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.巴利昔替尼治疗难治性大动脉炎：一家三级转诊中心的前瞻性队列研究。
RMD Open. 2024 Mar 22;10(1):e003985. doi: 10.1136/rmdopen-2023-003985.
4
Successful Use of Tofacitinib in Refractory Takayasu Arteritis: A Case Series.托法替布在难治性大动脉炎中的成功应用：病例系列
Mediterr J Rheumatol. 2023 Jul 31;34(3):356-362. doi: 10.31138/mjr.230929.su. eCollection 2023 Sep.
5
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.Janus 激酶抑制剂治疗巨细胞动脉炎的临床经验和安全性：来自瑞典的回顾性病例系列研究。
Front Immunol. 2023 May 25;14:1187584. doi: 10.3389/fimmu.2023.1187584. eCollection 2023.
6
Takayasu Arteritis is Associated with Impaired Arterial Stiffness: A Meta-Analysis of Observational Studies.高安动脉炎与动脉僵硬度受损相关：观察性研究的荟萃分析
Mediterr J Rheumatol. 2022 Dec 31;33(4):387-392. doi: 10.31138/mjr.33.4.387. eCollection 2022 Dec.
7
Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review.难治性高安动脉炎合并复发性坏疽性脓皮病：基于病例回顾的治疗挑战
Clin Rheumatol. 2023 May;42(5):1469-1477. doi: 10.1007/s10067-023-06506-x. Epub 2023 Jan 13.
8
Augmented PFKFB3-mediated glycolysis by interferon-γ promotes inflammatory M1 polarization through the JAK2/STAT1 pathway in local vascular inflammation in Takayasu arteritis.干扰素-γ 通过增强的 PFKFB3 介导的糖酵解作用促进 JAK2/STAT1 通路，从而在大动脉炎局部血管炎症中促进炎症型 M1 极化。
Arthritis Res Ther. 2022 Dec 12;24(1):266. doi: 10.1186/s13075-022-02960-1.
9
Advances in Takayasu arteritis: An Asia Pacific perspective.高安动脉炎的进展：亚太地区视角
Front Med (Lausanne). 2022 Aug 15;9:952972. doi: 10.3389/fmed.2022.952972. eCollection 2022.
10
Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib.糖皮质激素和托法替布治疗后与大动脉炎相关的生物标志物变化和分子特征
J Inflamm Res. 2022 Aug 3;15:4395-4407. doi: 10.2147/JIR.S369963. eCollection 2022.
本文引用的文献
1
Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib.对口服Janus激酶抑制剂托法替布有反应的难治性大动脉炎
Rheumatol Adv Pract. 2019 Dec 23;4(1):rkz050. doi: 10.1093/rap/rkz050. eCollection 2020.
2
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases.托法替布治疗难治性大动脉炎：2例病例描述
Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):234-235. Epub 2020 Jan 9.
3
A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.一例大动脉炎合并难治性溃疡性结肠炎患者经托法替布治疗成功
Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.
4
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.2018 年版 EULAR 大血管血管炎管理建议更新。
Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.
5
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.JAK-STAT 信号抑制在大中血管血管炎中的致病性免疫反应。
Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.
6
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).托珠单抗治疗难治性大动脉炎的疗效和安全性：来自日本一项随机、双盲、安慰剂对照、3 期临床试验（TAKT 研究）的结果。
Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30.
7
Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients.大动脉炎并发症的长期预后和预测因素：一项 318 例患者的多中心研究。
Circulation. 2017 Sep 19;136(12):1114-1122. doi: 10.1161/CIRCULATIONAHA.116.027094. Epub 2017 Jul 12.
8
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.类风湿关节炎JAK抑制剂的最新进展与展望：从实验台到临床应用
J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Epub 2015 Jul 7.
Zotero 插件